Related Experiment Video
Updated: May 6, 2026
Zebrafish Model of Neuroblastoma Metastasis
Published on: March 14, 2021
Novel SMARCA4::VEZF1 Rearrangement in Pediatric Sarcomas
Libing Fu1, Rongjun Mao2,3, Changliang Zhang4,5
1Department of Pathology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Abstract:
The SMARCA4 gene encodes a key ATPase subunit of the SWI/SNF (BAF) chromatin-remodeling complex, which plays an essential role in regulating transcription and cellular differentiation. Loss-of-function alterations of SMARCA4 are common in various human cancers, including sarcomas; however, rare SMARCA4 fusion events, presumably resulting in gain of function, have also been reported. We present two pediatric soft-tissue sarcomas harboring a novel, recurrent in-frame fusion between SMARCA4 and VEZF1 (Vascular Endothelial Zinc Finger 1), a transcription factor important for vascular development and angiogenesis. The predicted fusion protein contains the N-terminal QLQ protein interaction domain of SMARCA4 and preserves most of VEZF1's C2H2 zinc-finger DNA-binding domains. Interestingly, another component of the BAF complex, SS18, has also been reported to be fused to VEZF1 in uterine sarcoma. We propose that fusion of BAF complex components to VEZF1 leads to aberrant recruitment of chromatin-remodeling activity to VEZF1 target loci, resulting in altered chromatin architecture, dysregulated VEZF1-dependent transcription, and tumorigenesis.
Insights
Pediatric soft-tissue sarcomas can harbor novel SMARCA4-VEZF1 gene fusions. These fusions may lead to altered gene regulation and tumor development by aberrantly recruiting chromatin remodelers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- SMARCA4 is crucial for the SWI/SNF (BAF) chromatin-remodeling complex, vital for gene regulation and differentiation.
- Loss-of-function SMARCA4 alterations are frequent in cancers, but rare gain-of-function fusions have been observed.
Purpose of the Study:
- To identify and characterize novel gene fusions in pediatric soft-tissue sarcomas.
- To investigate the potential role of SMARCA4-VEZF1 fusions in tumorigenesis.
Main Methods:
- Somatic fusion detection in pediatric soft-tissue sarcoma samples.
- Analysis of predicted fusion protein domains and comparison with known oncogenic fusions.
- Hypothesizing the mechanism of tumorigenesis driven by BAF complex component fusions.
Main Results:
- Discovery of a recurrent, in-frame fusion between SMARCA4 and VEZF1 in two pediatric soft-tissue sarcomas.
- The fusion protein retains SMARCA4's N-terminal interaction domain and VEZF1's DNA-binding domains.
- Similar SS18-VEZF1 fusions have been reported in uterine sarcoma, suggesting a pattern.
Conclusions:
- SMARCA4-VEZF1 fusions represent a potential oncogenic mechanism in pediatric sarcomas.
- These fusions may aberrantly recruit chromatin-remodeling complexes to VEZF1 target genes.
- This aberrant recruitment can alter chromatin structure, dysregulate transcription, and drive tumor formation.
More Related Videos
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
02:07Tumor Progression
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...